Published in Nat Med on March 07, 2010
Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 5.52
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (2012) 2.92
HIV latency. Cold Spring Harb Perspect Med (2011) 2.90
HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe (2011) 2.59
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
Ex vivo expanded hematopoietic stem cells overcome the MHC barrier in allogeneic transplantation. Cell Stem Cell (2011) 1.91
Eradicating HIV-1 infection: seeking to clear a persistent pathogen. Nat Rev Microbiol (2014) 1.65
HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood (2013) 1.51
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem (2011) 1.45
Macrophages and their relevance in Human Immunodeficiency Virus Type I infection. Retrovirology (2012) 1.41
Are T cells the only HIV-1 reservoir? Retrovirology (2016) 1.39
Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions. Clin Dev Immunol (2012) 1.39
Developing strategies for HIV-1 eradication. Trends Immunol (2012) 1.38
Targeted DNA mutagenesis for the cure of chronic viral infections. J Virol (2012) 1.36
The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat Immunol (2011) 1.35
Expansion of monocytic myeloid-derived suppressor cells dampens T cell function in HIV-1-seropositive individuals. J Virol (2012) 1.32
Hematopoietic precursor cells isolated from patients on long-term suppressive HIV therapy did not contain HIV-1 DNA. J Infect Dis (2012) 1.30
Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res (2011) 1.29
HIV reservoirs and latency models. Virology (2011) 1.29
HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy. J Infect Dis (2012) 1.29
Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cell-mediated cytotoxicity. Proc Natl Acad Sci U S A (2014) 1.26
HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood (2011) 1.25
A flexible model of HIV-1 latency permitting evaluation of many primary CD4 T-cell reservoirs. PLoS One (2012) 1.23
Finding a cure for HIV: will it ever be achievable? J Int AIDS Soc (2011) 1.18
Cellular and molecular mechanisms involved in the establishment of HIV-1 latency. Retrovirology (2013) 1.18
Hematopoietic stem/precursor cells as HIV reservoirs. Curr Opin HIV AIDS (2011) 1.15
Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. Blood (2013) 1.13
Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One (2010) 1.13
Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother (2013) 1.12
New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond. Curr HIV/AIDS Rep (2012) 1.08
From reactivation of latent HIV-1 to elimination of the latent reservoir: the presence of multiple barriers to viral eradication. Bioessays (2013) 1.07
Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-κB activation. J Virol (2012) 1.07
Novel cell and gene therapies for HIV. Cold Spring Harb Perspect Med (2012) 1.07
CD4+ T cell depletion in human immunodeficiency virus (HIV) infection: role of apoptosis. Viruses (2011) 1.07
Patients with discordant responses to antiretroviral therapy have impaired killing of HIV-infected T cells. PLoS Pathog (2010) 1.05
HIV-1 pathogenesis: the virus. Cold Spring Harb Perspect Med (2012) 1.03
Nature, nurture and HIV: The effect of producer cell on viral physiology. Virology (2013) 1.02
Eradication therapies for HIV Infection: time to begin again. AIDS Res Hum Retroviruses (2011) 0.99
Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected indian rhesus macaques. Antimicrob Agents Chemother (2014) 0.99
HIV/AIDS eradication. Bioorg Med Chem Lett (2013) 0.98
Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis. J Neurovirol (2011) 0.98
Human immunodeficiency virus (HIV) latency: the major hurdle in HIV eradication. Mol Med (2012) 0.96
NF-κB/Rel: agonist and antagonist roles in HIV-1 latency. Curr Opin HIV AIDS (2011) 0.95
Achieving a cure for HIV infection: do we have reasons to be optimistic? J Antimicrob Chemother (2012) 0.95
CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression. J Infect Dis (2013) 0.95
New insights on human polyomavirus JC and pathogenesis of progressive multifocal leukoencephalopathy. Clin Dev Immunol (2013) 0.94
Hypomorphic mutation in the site-1 protease Mbtps1 endows resistance to persistent viral infection in a cell-specific manner. Cell Host Microbe (2011) 0.93
Dual-color HIV reporters trace a population of latently infected cells and enable their purification. Virology (2013) 0.92
Ex vivo gene therapy for HIV-1 treatment. Hum Mol Genet (2011) 0.92
HIV-1 Reservoirs During Suppressive Therapy. Trends Microbiol (2016) 0.92
MicroRNA-mediated restriction of HIV-1 in resting CD4+ T cells and monocytes. Viruses (2012) 0.90
Systemic responses during local viral infections: type I IFNs sound the alarm. Curr Opin Immunol (2011) 0.88
Effects of human immunodeficiency virus on the erythrocyte and megakaryocyte lineages. World J Virol (2013) 0.88
Introduction: challenges to finding a cure for HIV infection. Curr Opin HIV AIDS (2011) 0.88
Adaptor protein 1 promotes cross-presentation through the same tyrosine signal in major histocompatibility complex class I as that targeted by HIV-1. J Virol (2013) 0.87
Recent developments in human immunodeficiency virus-1 latency research. J Gen Virol (2013) 0.87
A Subset of CD4/CD8 Double-Negative T Cells Expresses HIV Proteins in Patients on Antiretroviral Therapy. J Virol (2015) 0.87
Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis. Future Virol (2010) 0.86
DNA cleavage enzymes for treatment of persistent viral infections: recent advances and the pathway forward. Virology (2014) 0.86
Mechanisms of HIV Transcriptional Regulation and Their Contribution to Latency. Mol Biol Int (2012) 0.86
Thirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors. AIDS Res Treat (2012) 0.86
Substance abuse, HIV-1 and hepatitis. Curr HIV Res (2012) 0.85
HIV-1 functional cure: will the dream come true? BMC Med (2015) 0.84
Vpr overcomes macrophage-specific restriction of HIV-1 Env expression and virion production. Cell Host Microbe (2014) 0.84
HIV quasispecies dynamics during pro-active treatment switching: impact on multi-drug resistance and resistance archiving in latent reservoirs. PLoS One (2011) 0.84
A model of HIV-1 infection with two time delays: mathematical analysis and comparison with patient data. Math Biosci (2011) 0.84
Tissue reservoirs of HIV. Curr Opin HIV AIDS (2016) 0.83
Transcriptional regulation of the chemokine co-receptor CCR5 by the cAMP/PKA/CREB pathway. Biomed Pharmacother (2011) 0.83
Hematopoietic cell transplantation and HIV cure: where we are and what next? Blood (2013) 0.82
Heterologous viral promoters incorporated into the human cytomegalovirus genome are silenced during experimental latency. J Virol (2013) 0.82
Proteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication. Retrovirology (2013) 0.82
Vpr Promotes Macrophage-Dependent HIV-1 Infection of CD4+ T Lymphocytes. PLoS Pathog (2015) 0.81
Fight or flight: regulation of emergency hematopoiesis by pyroptosis and necroptosis. Curr Opin Hematol (2015) 0.80
Therapeutic doses of irradiation activate viral transcription and induce apoptosis in HIV-1 infected cells. Virology (2015) 0.80
Functional properties of the HIV-1 long terminal repeat containing single-nucleotide polymorphisms in Sp site III and CCAAT/enhancer binding protein site I. Virol J (2014) 0.80
HIV-1 Latency and Eradication: Past, Present and Future. Curr HIV Res (2016) 0.80
Synergistic Activation of Latent HIV-1 Expression by Novel Histone Deacetylase Inhibitors and Bryostatin-1. Sci Rep (2015) 0.80
HIV persistence: chemokines and their signalling pathways. Cytokine Growth Factor Rev (2012) 0.80
Stem cell-based approaches to treating HIV infection. Curr Opin HIV AIDS (2011) 0.80
Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents. J Infect Dis (2017) 0.79
Successful isolation of infectious and high titer human monocyte-derived HIV-1 from two subjects with discontinued therapy. PLoS One (2013) 0.79
Potential implication of residual viremia in patients on effective antiretroviral therapy. AIDS Res Hum Retroviruses (2015) 0.79
HIV-associated lymphoma in the era of combination antiretroviral therapy: shifting the immunological landscape. Pathog Dis (2015) 0.79
Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions. Expert Rev Anti Infect Ther (2014) 0.79
Reactivation of latent HIV-1 provirus via targeting protein phosphatase-1. Retrovirology (2015) 0.79
Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers. PLoS Pathog (2016) 0.78
A polymorphism in the leptin gene promoter is associated with anemia in patients with HIV disease. Blood (2011) 0.78
Recombination can lead to spurious results in retroviral transduction with dually fluorescent reporter genes. J Virol (2013) 0.78
Impact of viral activators and epigenetic regulators on HIV-1 LTRs containing naturally occurring single nucleotide polymorphisms. Biomed Res Int (2015) 0.77
Wild-type measles virus interferes with short-term engraftment of human CD34+ hematopoietic progenitor cells. J Virol (2011) 0.77
CD4 is expressed on a heterogeneous subset of hematopoietic progenitors, which persistently harbor CXCR4 and CCR5-tropic HIV proviral genomes in vivo. PLoS Pathog (2017) 0.77
HIV-1 Is Restricted prior to Integration of Viral DNA in Primary Cord-Derived Human CD34+ Cells. J Virol (2015) 0.76
Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID In A Viral Outgrowth Assay. J Acquir Immune Defic Syndr (2016) 0.76
Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection. Nat Rev Drug Discov (2016) 0.76
Hematopoietic stem cells and HIV infection. J Infect Dis (2013) 0.76
Tetherin Antagonism by HIV-1 Group M Nef Proteins. J Virol (2016) 0.76
Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol (1998) 8.21
GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature (1992) 7.41
Quiescent T lymphocytes as an inducible virus reservoir in HIV-1 infection. Science (1991) 7.15
Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med (1996) 7.08
HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature (1998) 6.94
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation. Blood (2008) 2.79
CD4 down-modulation during infection of human T cells with human immunodeficiency virus type 1 involves independent activities of vpu, env, and nef. J Virol (1996) 2.61
Primitive hematopoietic cells resist HIV-1 infection via p21. J Clin Invest (2007) 1.88
Design of HIV vectors for efficient gene delivery into human hematopoietic cells. Mol Ther (2002) 1.85
Requirements for efficient production and transduction of human immunodeficiency virus type 1-based vectors. J Virol (1999) 1.32
Analysis of human immunodeficiency virus type 1 integration by using a specific, sensitive and quantitative assay based on real-time polymerase chain reaction. Virus Genes (2006) 1.31
Neither human immunodeficiency virus-1 (HIV-1) nor HIV-2 infects most-primitive human hematopoietic stem cells as assessed in long-term bone marrow cultures. Blood (1998) 1.19
A new improved method for the concentration of HIV-1 infective particles. J Virol Methods (2002) 1.11
Simplified lentivirus vector production in protein-free media using polyethylenimine-mediated transfection. J Virol Methods (2009) 1.10
Bone marrow CD34(+) cells and megakaryoblasts secrete beta-chemokines that block infection of hematopoietic cells by M-tropic R5 HIV. J Clin Invest (1999) 1.06
Phorbol esters induce differentiation of human CD34+ hemopoietic progenitors to dendritic cells: evidence for protein kinase C-mediated signaling. J Immunol (1998) 1.02
CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood (1995) 0.99
Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med (2012) 6.99
HIV-1 utilizes the CXCR4 chemokine receptor to infect multipotent hematopoietic stem and progenitor cells. Cell Host Microbe (2011) 2.59
Human immunodeficiency virus type 1 Nef: adapting to intracellular trafficking pathways. Microbiol Mol Biol Rev (2006) 2.25
HIV-1 Nef disrupts MHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail. J Cell Biol (2004) 1.84
Detection of vaccinia DNA in the blood following smallpox vaccination. JAMA (2006) 1.83
Blood culture contamination: a randomized trial evaluating the comparative effectiveness of 3 skin antiseptic interventions. Infect Control Hosp Epidemiol (2012) 1.61
HIV-1 Nef targets MHC-I and CD4 for degradation via a final common beta-COP-dependent pathway in T cells. PLoS Pathog (2008) 1.50
Epigenetic silencing of engineered L1 retrotransposition events in human embryonic carcinoma cells. Nature (2010) 1.47
Non-AIDS-defining cancers: should antiretroviral therapy be initiated earlier? AIDS Read (2008) 1.43
The failure of years of experience with electrocardiographic transmission from paramedics to the hospital emergency department to reduce the delay from door to primary coronary intervention below the 90-minute threshold during acute myocardial infarction. J Electrocardiol (2006) 1.38
The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat Immunol (2011) 1.35
Nef-mediated disruption of HLA-A2 transport to the cell surface in T cells. J Virol (2003) 1.32
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood (2010) 1.27
Direct binding of human immunodeficiency virus type 1 Nef to the major histocompatibility complex class I (MHC-I) cytoplasmic tail disrupts MHC-I trafficking. J Virol (2002) 1.26
The tyrosine binding pocket in the adaptor protein 1 (AP-1) mu1 subunit is necessary for Nef to recruit AP-1 to the major histocompatibility complex class I cytoplasmic tail. J Biol Chem (2007) 1.21
Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma. Blood (2014) 1.16
Hematopoietic stem/precursor cells as HIV reservoirs. Curr Opin HIV AIDS (2011) 1.15
HIV-1 Nef disrupts antigen presentation early in the secretory pathway. J Biol Chem (2005) 1.12
HIV-1 Nef disrupts intracellular trafficking of major histocompatibility complex class I, CD4, CD8, and CD28 by distinct pathways that share common elements. J Virol (2011) 1.10
Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia. Blood (2011) 1.09
Latent HIV-1 infection occurs in multiple subsets of hematopoietic progenitor cells and is reversed by NF-κB activation. J Virol (2012) 1.07
The emerging role of HLA-C in HIV-1 infection. Immunology (2011) 1.06
A novel trafficking signal within the HLA-C cytoplasmic tail allows regulated expression upon differentiation of macrophages. J Immunol (2008) 1.06
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study. Br J Haematol (2013) 1.04
Bartonella henselae infections in solid organ transplant recipients: report of 5 cases and review of the literature. Medicine (Baltimore) (2012) 1.02
Packaging of host mY RNAs by murine leukemia virus may occur early in Y RNA biogenesis. J Virol (2009) 1.01
Rev activity determines sensitivity of HIV-1-infected primary T cells to CTL killing. Immunity (2003) 1.00
HLA-B44 polymorphisms at position 116 of the heavy chain influence TAP complex binding via an effect on peptide occupancy. J Immunol (2006) 0.97
Cardiovascular implantable electronic device associated infections. Infect Dis Clin North Am (2012) 0.95
CD133+ hematopoietic progenitor cells harbor HIV genomes in a subset of optimally treated people with long-term viral suppression. J Infect Dis (2013) 0.95
Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr (2014) 0.90
HIV immune evasion disruption of antigen presentation by the HIV Nef protein. Adv Virus Res (2011) 0.89
Comparison of the predicted population coverage of tuberculosis vaccine candidates Ag85B-ESAT-6, Ag85B-TB10.4, and Mtb72f via a bioinformatics approach. PLoS One (2012) 0.88
Adaptor protein 1 promotes cross-presentation through the same tyrosine signal in major histocompatibility complex class I as that targeted by HIV-1. J Virol (2013) 0.87
Mycobacterium neoaurum bloodstream infection: report of 4 cases and review of the literature. Clin Infect Dis (2007) 0.86
The evolution of resistant Candida species in cancer centers: implications for treatment and prophylaxis. Cancer (2008) 0.85
Pharmacokinetics of different formulations of oral azacitidine (CC-486) and the effect of food and modified gastric pH on pharmacokinetics in subjects with hematologic malignancies. J Clin Pharmacol (2014) 0.85
Experience with community-based amphotericin B infusion therapy. Pharmacotherapy (2005) 0.84
Assembly and intracellular trafficking of HLA-B*3501 and HLA-B*3503. Immunogenetics (2009) 0.84
Species-specific effects of HIV-1 Nef-mediated MHC-I downmodulation. Virology (2002) 0.83
Down-modulation of CD8αβ is a fundamental activity of primate lentiviral Nef proteins. J Virol (2011) 0.83
Interferon alfa therapy: toward an improved treatment for HIV infection. J Infect Dis (2012) 0.82
Molecular mechanisms of HIV immune evasion of the innate immune response in myeloid cells. Viruses (2012) 0.82
Factors associated with seroconversion after standard dose hepatitis B vaccination and high-dose revaccination among HIV-infected patients. HIV Clin Trials (2011) 0.82
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies. Cancer Chemother Pharmacol (2013) 0.80
Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions. Expert Rev Anti Infect Ther (2014) 0.79
Towards a cure for HIV: the identification and characterization of HIV reservoirs in optimally treated people. Cell Res (2010) 0.79
Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission. Ann Hematol (2015) 0.79
Successful treatment of pulmonary zygomycosis in two transplant recipients with liposomal amphotericin B and partial surgical resection followed by posaconazole. Mycoses (2009) 0.79
Serogroup B Meningococcal Disease Outbreak and Carriage Evaluation at a College - Rhode Island, 2015. MMWR Morb Mortal Wkly Rep (2015) 0.79
Overcoming resistance in chronic myelogenous leukemia. Leuk Lymphoma (2009) 0.79
The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia. Am J Hematol (2009) 0.78
HIV-infected patients with anal carcinoma who subsequently developed oral squamous cell carcinoma: report of 2 cases. J Int Assoc Physicians AIDS Care (Chic) (2008) 0.78
Clinical roundtable monograph: Unmet needs in the management of chronic myelogenous leukemia. Clin Adv Hematol Oncol (2012) 0.77
Cutaneous manifestations of endemic mycoses. Curr Infect Dis Rep (2013) 0.77
Serogroup B Meningococcal Disease Vaccine Recommendations at a University, New Jersey, USA, 2016. Emerg Infect Dis (2017) 0.77
A Biochip with a 3D microfluidic architecture for trapping white blood cells. Sens Actuators B Chem (2013) 0.75
CD9 phones home with a TEM of its own. Blood (2011) 0.75
Rapid Laboratory Identification of Neisseria meningitidis Serogroup C as the Cause of an Outbreak - Liberia, 2017. MMWR Morb Mortal Wkly Rep (2017) 0.75
Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2017) 0.75
Unfavorable-risk acute myeloid leukemia dissected. Curr Opin Hematol (2016) 0.75
1776: HIGH-DOSE INTRAVENOUS QUINIDINE GLUCONATE RESULTS IN DELAYED CARDIAC TOXICITY. Crit Care Med (2016) 0.75